LIGAND PHARMACEUTICALS INC

LGND

Form 4 • Statement of Changes in Beneficial Ownership

SEC Accession Number: 0002001011-26-000018
Filing date: Mar 4, 2026
Earliest execution date: Mar 2, 2026
Reporting Owners: KOZARICH JOHN W (Director)

Summary

Type

Sell

Net shares

-467

% of shares

-1.08%

Amount (USD)

$93,632

Insider confidence score

46.3 out of 100

Positive

  • Under Rule 10b5-1 trading plan

Negative

  • Moderate scheduled sell (<2% of shares)
  • Significant sell amount ($50K+)

Stock transactions

Transaction 1

Security

Common Stock

Action

Sell

Date

2026-03-02

Code

S

Net shares

-47.0

Price per Share

$197.14

Amount (USD)

$9,265.57

Acquired/Disposed

Disposed

Shares Owned Before

43,187.0

Shares Owned After

43,140.0

Transaction 2

Security

Common Stock

Action

Sell

Date

2026-03-02

Code

S

Net shares

-204.0

Price per Share

$199.69

Amount (USD)

$40,736.64

Acquired/Disposed

Disposed

Shares Owned Before

43,140.0

Shares Owned After

42,936.0

Transaction 3

Security

Common Stock

Action

Sell

Date

2026-03-02

Code

S

Net shares

-41.0

Price per Share

$200.40

Amount (USD)

$8,216.56

Acquired/Disposed

Disposed

Shares Owned Before

42,936.0

Shares Owned After

42,895.0

Transaction 4

Security

Common Stock

Action

Sell

Date

2026-03-02

Code

S

Net shares

-83.0

Price per Share

$201.65

Amount (USD)

$16,736.72

Acquired/Disposed

Disposed

Shares Owned Before

42,895.0

Shares Owned After

42,812.0

Transaction 5

Security

Common Stock

Action

Sell

Date

2026-03-02

Code

S

Net shares

-50.0

Price per Share

$202.54

Amount (USD)

$10,126.94

Acquired/Disposed

Disposed

Shares Owned Before

42,812.0

Shares Owned After

42,762.0

Transaction 6

Security

Common Stock

Action

Sell

Date

2026-03-02

Code

S

Net shares

-42.0

Price per Share

$203.57

Amount (USD)

$8,549.94

Acquired/Disposed

Disposed

Shares Owned Before

42,762.0

Shares Owned After

42,720.0

Filing's footnotes

1. The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on March 07, 2025, in accordance with Rule 10b5-1.

2. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $197.0650 to $197.2000. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

3. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $199.4100 to $200.0550. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

4. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $200.1050 to $200.8400. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

5. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $201.2150 to $202.0500. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

6. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $202.1500 to $202.8700. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

ℹ️ Filed under Rule 10b5-1 trading plan

This page is for informational purposes only. While we strive for accuracy, the summary may contain inaccuracies or omissions. Please refer to the official SEC filing for authoritative information. Open the SEC filing.